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Abstract
Acromegaly is caused by hypersecretion of growth hormone and resultant overproduction of insulin-
like growth factor-1 and is associated with increased mortality and morbidity. Successful treatment
modalities have been developed and are used in a multistep approach allowing normal life expectancy
as well as improved quality of life in an increasing number of patients.
Introduction and context
Acromegaly is a chronic progressive disorder due to
growth hormone (GH) hypersecretion and subsequent
elevated levels of insulin-like growth factor-1 (IGF-1). In
over 95% of cases the etiology can be attributed to GH-
producing benign pituitary adenoma [1]. With an
estimated prevalence of 40-70 cases per million and an
incidence of 3-5 new cases per million [2], it ranks as a
rare disease. Several recent studies suggest, however, that
these rates may be underestimates and report prevalence
rates up to 130 cases per million [3,4] or even 1000 cases
per million for biochemical acromegaly, defined by
elevated IGF-1 levels [5]. Excess GH secretion leads to
disproportionate skeletal growth, coarse facial features,
soft tissue swelling as well as metabolic disorders and a
tendency for malignancies that inexorably result in
increased mortality and morbidity rates if the disease is
left untreated. Since these unfavorable effects have
insidious onset, the diagnosis is often delayed up to
7 years after initial presentation of symptoms [1,6].
Although significant advances have been made in the
past decades with the introduction of highly sensitive
assays for GH and IGF-1, relatively little progress has
been achieved in early recognition.
Mortality rates are closely related to the degree of GH and
IGF-1 hypersecretion and reducing their levels to normal
ranges can confer life expectancy similar to that of the
general population [7]. Therapeutic goals include control
of GH and IGF-1 levels, tumor volume reduction for
alleviating symptoms of mass effect and concomitant
neurological disorders, preservation of pituitary func-
tion, improvement of long-term mortality and morbid-
ity, and prevention of disease recurrence as well as
increasing the quality of life of patients.
Recent advances
Several consensus statements and clinical guidelines
[8-11] have been published recently clearly defining
criteria for good disease control: suppression of GH to
<0.4 mg/l during oral glucose tolerance test or random
GH values <1 mg/l (using ultrasensitive assays) and age-
adjusted normal levels of IGF-1. Strategies are now
available to help physicians achieve more effective
treatment of acromegaly. Surgery, pharmacological
therapy, and radiotherapy are employed in a step-like
approach to maintain disease control.
Surgery
Transsphenoidal surgery is the preferred first-line treat-
ment for patients with acromegaly that have intrasellar
microadenomas, noninvasive macroadenomas or
patients in whom the tumor is causing compression
symptoms. Surgery can lead to rapid normalization of
GH levels, it relieves symptoms of compression if present
and may achieve total cure in up to 56-70% of
appropriate patients [12,13]. Major predictors of out-
come of surgery are tumor size and invasiveness,
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gical team. In patients with well-circumscribed micro-
adenoma,successratesmayreach78-95%,whileinvasive
macroadenomas, constituting more than two-thirds of
cases at diagnosis, can be controlled in less than 50%
[12,14]. Nevertheless, surgical debulking of unresectable
adenomasmayresultinbetter postoperativecontrolwith
somatostatin receptor ligands (SRLs) [15,16]. The scope
of lesions that can be successfully removed is further
widened by recently developed technical advances, such
as endoscope-assisted microsurgery, three-dimensional
navigation, and intra-operative magnetic resonance
imaging, but properly conducted comparative studies
are still lacking.
Pharmacological therapy
Three classes of drugs are currently available for the
treatment of acromegaly: SRLs, GH receptor antagonists,
and dopamine agonists. Pharmacological therapy is
mainly indicated when surgery fails to achieve remission
but is increasingly considered as primary medical
treatment. The traditional subgroups of patients that
were considered as good candidates for primary medical
therapy (mainly with SRLs) included patients with
contraindications to, or unwillingness to undergo,
operative intervention or those with tumors unlikely to
be cured by surgery alone [8]. A recent study has
suggested that SRLs might have similar utility to surgery
as first-line primary therapy in unselected patients,
although confirmatory data are awaited [17].
Somatostatin receptor ligands
SRLs are analogues of natural somatostatin and exert
their effects by binding to somatostatin receptors
(SSTRs) on pituitary somatotrope cells, thus suppres-
sing GH secretion. Commercially available drugs
include octreotide and lanreotide and long-acting
preparations have been developed for both molecules,
increasing patient comfort and compliance. These
agents effectively lower GH levels to <1 mg/l in 48-
57% and normalize IGF-1 levels in 47-67% of patients
a ss h o w ni nar e c e n tm e t a - a n a l y s i s[ 1 8 ] .H o w e v e r ,
many patients in clinical trials were pre-selected for
responsiveness to SRL and lesser efficacy may be
expected in unselected populations. When applied as
primary therapy in unselected patients, they achieved
normalization of GH and IGF-1 in 34% and 44% of
subjects, respectively [19]. Apart from their antisecre-
tory efficacy, SRLs also reduce tumor volume in
approximately 24-57% of patients, with greater effect
when used as primary therapy (30-80%) compared
to adjuvant treatment (9-28%) [20]. Their role as
primary medical therapy is still evolving. Current
guidelines advocate SRLs in selected patients whose
co-morbidities present a risk for surgery and also in
patients who have invasive tumors where complete
removal is unlikely [8]. Controversy also exists over
whether SRLs should be considered as pre-operative
treatment. In a recent study Carlsen et al. [21] showed
that pre-operative octreotide in patients with macro-
adenomas led to 50% cure rates after surgery compared
to 23% in non-treated subjects, confirming previous
results by Stevenaert and Beckers [22], while several
other studies failed to demonstrate such benefits [23].
It should be noted, however, that in the Carlsen et al.
study patients were evaluated only 3 months after
surgery and control rates over the long term are still
lacking. [24]. The long-acting preparations of both
octreotide and lanreotide seem to have relatively
equivalent efficacy for acromegaly treatment [25].
Currently, two other molecules are undergoing clinical
research – pasireotide, a novel somatostatin analog
that binds with high affinity to SSTR1, SSTR2, SSTR3,
and SSTR5, and a chimeric compound, dopastatin, that
acts as a SSTR2 and type 2 dopamine receptor ligand.
In a recent phase II study, pasireotide appeared to be
superiortooctreotideintermsoftheproportionofpatients
attaining full biochemical response after 1 month;
shrinkage after 3 months of pasireotide treatment [26].
Pegvisomant
Pegvisomant is the only currently available GH receptor
antagonist. It acts by preventing GH receptor dimeriza-
tion, thus blocking GH effects in the periphery, including
the production of IGF-1. Currently, it is indicated when
other treatment modalities have failed to achieve IGF-1
normalization. Early trials have reported that this
compound effectively suppresses IGF-1 levels within
normal ranges in up to 97% of patients [27], but a recent
prospective study demonstrates that such rates are
difficult to obtain in clinical settings [28]. The mechan-
ism of action of GH receptor antagonists raises concerns
about tumor growth but recent studies have been
reassuring in that regard [28,29]. Nevertheless, monitor-
ing of tumor mass is advisable in all patients receiving
pegvisomant. Combined therapy with SRLs and pegvi-
somant appears to be as equally effective as pegvisomant
monotherapy but with improved cost-effectiveness
because of the lower dose needed to achieve IGF-1
normalization [30].
Dopamine agonists
Dopamine agonists have been used for the management
ofacromegalyformorethan30yearsbutlowefficacy
success rates are reported with cabergoline in tumors
with prolactin co-secretion and milder disease activity.
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[31]
more than a third of them had some degree of tumor
has
discouragedtheiradoptionasmonotherapy .BetterRadiotherapy
Radiotherapy can be employed as third- or second-line
treatment in patients with persistent or recurrent tumors
after surgery and who are resistant or intolerant to
pharmacological agents. Conventional fractionated
radiotherapy leads to biochemical remission in 40-50%
of patients after 10 years but is associated with a high risk
of hypopituitarism, possible development of secondary
brain tumors, and an increase in mortality due to
cerebro-vascular disease [32]. The use of stereotactic
radiosurgery, delivering single fraction focused radiation,
results in shorter response times but the long-term
efficacy after 10 years of follow-up remains similar to
conventional therapy [33].
Implications for clinical practice
Significant advances in the management of acromegaly
have been made in recent years and prognosis for this
chronic disease has greatly improved. The combined
use of the different treatment approaches allows for
attaining disease control or even complete cure in an
increasing proportion of patients. A vast spectrum of
clinical studies has provided a lot of evidence for the
p l a c eo ft h ea v a i l a b l eo p t i o n si nt h et r e a t m e n t
strategies included in current guidelines. Transsphe-
noidal surgery performed by experienced neurosur-
geons remains the treatment of first choice in many
cases. When surgery fails to achieve remission or
cannot be used, adjunctive medical therapy may be
employed and SRLs are generally preferred as first-line
pharmacological treatment. They may also be used as
primary and preoperative therapy but whether this will
be beneficial for patients still remains to be seen.
Pegvisomant is very potent in maintaining biochemical
control but its widespread use is limited by its high
cost. Radiotherapy is, in many instances, reserved for
the most aggressive or resistant tumors.
Despite the progress in management, acromegaly still
remains under-diagnosed and under-recognized as a
recent study reports [34]. The probability for successful
outcomes of treatment is closely related to disease
severity and presence of co-morbidities, suggesting that
an increased level of suspicion is needed, especially in
primary care, when dealing with this disease.
Abbreviations
GH,growthhormone;IGF-1,insulin-likegrowthfactor1;
SRL, somatostatin receptor ligand; SSTR, somatostatin
receptor.
Competing interests
The authors declare that they have no competing
interests.
References
1. Melmed S: Medical progress: acromegaly. N Engl J Med 2006,
355:2558-73.
2. Holdaway IM, Rajasoorya C: Epidemiology of acromegaly. Pituitary
1999, 2:29-41.
3. Daly AF, Tichomirowa MA, Beckers A: The epidemiology and
genetics of pituitary adenomas. Best Pract Res Clin Endocrinol
Metab 2009, 23:543-54.
4. Daly AF, Petrossians P, Beckers A: An overview of the
epidemiology and genetics of acromegaly. J Endocrinol Invest
2005, 28:67-9.
5. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK: High
prevalence of biochemical acromegaly in primary care
patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008,
69:432-5.
F1000 Factor 3.0 Recommended
Evaluated by Philippe Chanson 24 Apr 2008
6. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A:
Changing patterns in diagnosis and therapy of acromegaly
over two decades. J Clin Endocrinol Metab 2008, 93:2035-41.
7. Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing
mortality in acromegaly. J Clin Endocrinol Metab 2004, 89:667-74.
8. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D,
Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K,
Giustina A; Acromegaly Consensus Group: Guidelines for acro-
megaly management: an update. J Clin Endocrinol Metab 2009,
94:1509-17.
F1000 Factor 6.0 Must Read
Evaluated by Maria Chiara Zatelli 07 Sep 2009
9. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA,
Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E,
Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA,
Giustina A: Consensus statement: medical management of
acromegaly. Eur J Endocrinol 2005, 153:737-40.
10. Chanson P, Bertherat J, Beckers A, Bihan H, Brue T, Caron P,
Chabre O, Cogne M, Cortet-Rudelli C, Delemer B, Dufour H,
Gaillard R, Gueydan M, Morange I, Souberbielle JC, Tabarin A; Club
Français De L’hypophyse (French Pituitary Club); Société Française
Dendocrinologie (French Endocrinology Society): French consensus
on the management of acromegaly. Ann Endocrinol (Paris) 2009,
70:92-106.
11. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S,
Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S: A consensus on
criteria for cure of acromegaly. J Clin Endocrinol Metab 2010,
[Epub ahead of print].
12. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in
668 patients with acromegaly using current criteria of
biochemical ‘cure’. Eur J Endocrinol 2005, 152:379-87.
13. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr: Surgical manage-
ment of GH-secreting pituitary adenomas: an outcome
study using modern remission criteria. JC l i nE n d o c r i n o lM e t a b
2001, 86:4072-7.
1 4 . A b eT ,L u d e c k eD K :Effects of preoperative octreotide
treatment on different subtypes of 90 GH-secreting pituitary
adenomas and outcome in one surgical centre. Eur J Endocrinol
2001, 145:137-45.
15. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-
Socin H, Stevenaert A, Chanson P, Beckers A: Gross total
resection or debulking of pituitary adenomas improves
hormonal control of acromegaly by somatostatin analogs.
Eur J Endocrinol 2005, 152:61-6.
16. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-
Sanderson V, Rowlers S, Trainer PJ, Wass JA: Surgical debulking of
pituitary macroadenomas causing acromegaly improves
control by lanreotide. Clin Endocrinol (Oxf) 2008, 68:970-5.
17. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR,
Hmissi A, Rees A, Reincke M, Safari M, T’Sjoen G, Bouterfa H,
Page 3 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:54 http://f1000.com/reports/medicine/content/2/54Cuneo RC: Octreotide LAR vs. surgery in newly diagnosed
patients with acromegaly: a randomized, open-label, multi-
centre study. Clin Endocrinol (Oxf) 2009, 70:757-68.
18. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S,
Rabinowitz D: Long-acting somatostatin analog therapy of
acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005,
90:4465-73.
19. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ,
Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401
Study Group: A prospective, multicentre study to investigate
the efficacy, safety and tolerability of octreotide LAR (long-
acting repeatable octreotide) in the primary therapy of
patients with acromegaly. Clin Endocrinol (Oxf) 2007, 66:859-68.
20. Bevan JS: Clinical review: The antitumoral effects of somatos-
tatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005,
90:1856-63.
21. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S,
Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL,
Bollerslev J; Preoperative Octreotide Treatment of Acromegaly
study group: Preoperative octreotide treatment in newly
diagnosed acromegalic patients with macroadenomas
increases cure short-term postoperative rates: a prospective,
randomized trial. J Clin Endocrinol Metab 2008, 93:2984-90.
22. Stevenaert A, Beckers A: Presurgical octreotide: treatment in
acromegaly. Metabolism 1996, 45:72-4.
23. Klibanski A, Melmed S, Clemmons DR, Colao A, Cunningham RS,
Molitch ME, Vinik AI, Adelman DT, Liebert KJ: The endocrine
tumor summit 2008: appraising therapeutic approaches for
acromegaly and carcinoid syndrome. Pituitary 2009, [Epub ahead
of print].
24. Beckers A: Does preoperative somatostatin analog treatment
improve surgical cure rates in acromegaly? A new look at an
old question. J Clin Endocrinol Metab 2008, 93:2975-7.
25. Murray RD, Melmed S: A critical analysis of clinically available
somatostatin analog formulations for therapy of acromegaly.
J Clin Endocrinol Metab 2008, 93:2957-68.
26. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R,
Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide
Acromegaly Study Group: Pasireotide (SOM230) demonstrates
efficacy and safety in patients with acromegaly: a rando-
mized, multicenter, phase ii trial. J Clin Endocrinol Metab 2010,
95:2781-9.
F1000 Factor 6.0 Must Read
Evaluated by Diego Ferone 16 Jun 2010
27. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL,
Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML,
Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G,
Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA,
Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of
acromegaly with pegvisomant, a growth hormone receptor
antagonist. Lancet 2001, 358:1754-9.
28. Trainer PJ: ACROSTUDY: the first 5 years. Eur J Endocrinol 2009,
161(Suppl 1):S19-24.
Changes Clinical Practice
F1000 Factor 6.0 Must Read
Evaluated by Maria Chiara Zatelli 25 Feb 2010
29. Buhk JH, Jung S, Psychogios MN, Göricke S, Hartz S, Schulz-Heise S,
Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M,
Buchfelder M, Knauth M: Tumor volume of growth hormone-
secreting pituitary adenomas during treatment with pegvi-
somant: a prospective multicenter study. J Clin Endocrinol Metab
2010, 95:552-8.
F1000 Factor 3.0 Recommended
Evaluated by Marcello Bronstein 09 Jun 2010
30. Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ:
A randomized, controlled, multicentre trial comparing
pegvisomant alone with combination therapy of pegvisomant
and long-acting octreotide in patients with acromegaly. Clin
Endocrinol (Oxf) 2009, 71:549-57.
F1000 Factor 3.0 Recommended
Evaluated by Maura Arosio 06 Apr 2010
31. Moyes VJ, Metcalfe KA, Drake WM: Clinical use of cabergoline as
primary and adjunctive treatment for acromegaly. Eur J
Endocrinol 2008, 159:541-5.
32. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS:
Growth hormone and pituitary radiotherapy, but not serum
insulin-like growth factor-I concentrations, predict excess
mortality in patients with acromegaly. J Clin Endocrinol Metab
2004, 89:1613-7.
33. Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P,
Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T: Long-
term results of stereotactic radiosurgery in secretory
pituitary adenomas. J Clin Endocrinol Metab 2009, 94:3400-7.
F1000 Factor 3.0 Recommended
Evaluated by Francesco Minuto 09 Jul 2009
34. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM,
Freda PU: Features at diagnosis of 324 patients with
acromegaly did not change from 1981 to 2006; Acromegaly
remains under-recognized and under-diagnosed. Clin Endocrinol
(Oxf) 2009, 72:203-8.
Page 4 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:54 http://f1000.com/reports/medicine/content/2/54